After four years of work, researchers at the Wellcome Trust Sanger Institute and colleagues have elucidated the prevalence and signature of somatic mutations in human protein kinases. The findings, recently reported in Nature, have provided surprising insights into the number of kinases that may be legitimate targets for cancer treatment, and challenged conventional thinking about which kinases should be priorities for drug developers.

The paper has already led some companies to change their research strategies.